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P U B L I S H E D B Y E L S E V I E R I N C .LettersTAVR-Associated
Prosthetic Valve
Infective Endocarditis
Results of a Large, Multicenter RegistryIn this study, we report the incidence, causes, and
outcomes of prosthetic valve infective endocarditis
(PIE) in 2,572 consecutive patients who underwent
transcatheter aortic valve replacement (TAVR) (1,191
balloon-expandable transcatheter heart valves [THVs]
[Edwards Sapien, Edwards Lifesciences Inc., Irvine,
California], 1,343 self-expandable THVs [CoreValve,
Medtronic, Minneapolis, Minnesota], and 38 other) in
14 centers between January 2008 and April 2013. Data
were collected by retrospective review of hospital re-
cords using a standardized case report form conforming
to the Valve Academic Research Consortium-2 criteria.
All sites ensured ethics committee approval. We
divided the onset of endocarditis into: 1) early-onset,
diagnosed within 60 days of TAVR; 2) intermediate,
between 60 and 365 days; and 3) late-onset, after
365 days (1–3). A total of 29 patientswere identiﬁedwith
TAVR-PIE (incidence 1.13% [95% conﬁdence interval:
0.76% to 1.62%]). Patients constituted a high-risk
group characterized by advanced age (80  6 years),
high Society of Thoracic Surgeons score (13  9), and
Logistic EuroSCORE (23  13). The majority (72%) had
at least 1 pre-existing predisposing risk factor for
infective endocarditis (IE), and 59% had >1 risk factor.
The majority (55%) of procedures were performed
in a cardiac catheterization suite, 34% in a hybrid
suite, and 11% in a surgical theatre. All patients re-
ceived antimicrobial prophylaxis according to insti-
tutional practice. Incidence of TAVR-PIE was 1.1%
(23 of 2,133) and 1.98% (6 of 303) after transfemoral
and transapical TAVR, respectively. The incidence of
TAVR-PIE was 1.93% (23 of 1,191) and 0.45% (6 of 1,343)
after balloon-expandable and self-expandable THVs
implantation, respectively. There was no evidence of
a pattern or change in the onset of TAVR-PIE as
experience with TAVR increased in the participating
centers. Three patients underwent an aortic valve-
in-valve procedure and were diagnosed with
intermediate-onset TAVR-PIE. Overall median time toonset of IE symptoms was 158 days (range: 3 to
800 days). Diagnosis of early-onset TAVR-PIE was
established in 28% (n ¼ 8), intermediate-onset in 52%
(n ¼ 15) and late-onset in 20% (n ¼ 6), resulting in a
higher incidence within the ﬁrst 12 months after TAVR
(80%) and lower rates of late-onset (20%) if contrasted
to surgical prosthetic valve endocarditis (PVE) (3).
Patients commonly had a fever (76%), and heart fail-
ure was observed in one-third of the population,
whereas 9 patients had embolic events during the
course of IE (8 cerebrovascular accident [CVA] events
and 1 ST-segment elevation myocardial infarction).
Classic IE signs were infrequent. “Deﬁnite IE” was
diagnosed in 83% (n ¼ 24) and “possible IE” in
the remaining. Blood cultures were positive in 73%
(n ¼ 21); the most common causes were staphylococci
and enterococci in 50% of patients. Table 1 summarizes
pathogen information. Probable infective sources
were identiﬁed in >70% of cases.
In the early-onset group, staphylococcus aureus
and coagulase-negative staphylococci were the most
prevalent (50%), suggesting nosocomial infections.
Intermediate-onset IE is primarily healthcare-
associated and staphylococcal, enterococcal, and non-
viridans streptococcal species each accounted for 20%.
Identiﬁed sources of bacteremia were iatrogenic (n¼ 3),
recurrent bacteremia from systemic infections (n ¼ 2),
and systemic diseases (n ¼ 4) (Osler-Weber-Rendu dis-
ease, colon cancer, advanced liver cirrhosis with previ-
ous IE, and advanced liver cirrhosis with drug-induced
immune suppression). In the late-onset group, cul-
tures grew staphylococci (33%) and enterococci (33%),
which does not mirror the post-surgical late-onset
PVE. Possible sources were recurrent bacteremia
from healthcare-associated infections (n ¼ 1), infec-
ted central catheter (n ¼ 1), and colonic polyps (n ¼ 1).
Although echocardiographic criteria are not easily
applicable in PVE (4), especially with TAVR (5),
combined transthoracic and transesophageal echo-
cardiography yielded important ﬁndings in 86% (25 of
29) of patients, with prosthetic vegetations being the
most common feature and mitral valve involvement
evident in 14% (4 of 29).
Clinical follow-up was complete in all 29 patients
(median 393 days [interquartile range: 191 to
785 days]), during which 62% (n ¼ 18) died. Of these,
13 died during hospitalization for IE and 5 during
TABLE 1 Microbiological Etiology in Patients With TAVR-PIE Diagnosis
All TAVR-PIE
(n ¼ 29)
Early-Onset
(n ¼ 8)
Intermediate-Onset
(n ¼ 15)
Late-Onset
(n ¼ 6)
Staphylococcus 9 (31) 4 (50) 3 (20) 2 (33)
S aureus 4 (14) 2 (25) 2 (13) —
Coagulase-negative staphylococci 5 (17) 2 (25) 1 (6.5) 2 (33)
Enterococci 6 (21) 1 (13) 3 (20) 2 (33)
Streptococcus 4 (14) — 4 (27) —
Viridans group streptococci 1 (3.4) — 1 (7) —
Other streptococci 3 (10) — 3 (20)
HACEK 1 (3.4) — 1 (7) —
Non-HACEK gram negative bacteria* 1 (3.4) — 1 (7) —
Granulicatella adiacens 1 (3.4) — 1 (7) —
Polymicrobial† 1† 1† —
Typical micro-organisms 13 (45) 2 (25) 9 (60) 2 (33)
Negative cultures 5 (17) 4 (50) 1 (7) —
N/A 3 (10) — 1 (7) 2 (33)
Values are n (%). *Escherichia coli. †Polymicrobial: 1 patient had blood cultures positive for E. faecalis and coagulase-negative staphylococci.
HACEK ¼ Haemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella species; N/A ¼ cultures not available;
PIE ¼ prosthetic valve infective endocarditis; TAVR ¼ transcatheter aortic valve replacement.
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2177follow-up (1 patient treated medically had a relapse of
endocarditis, 1 hemorrhagic CVA, 2 embolic CVA, and
1 recurrent sepsis). Three patients (3 of 29) underwent
surgery and 1 underwent TAVR-in-TAVR (1 of 29),
whereas the others were treated medically. In-
hospital mortality for the surgical group was 67%
(2 of 3); the surviving patient is still doing well, and
the TAVR-in-TAVR patient is stable but with persis-
tent severe mitral regurgitation. The only univariate
predictor of all-cause mortality was the presence of
chronic kidney disease (hazard ratio: 3.67; 95% con-
ﬁdence interval: 1.2 to 11.2; p ¼ 0.023).
To our knowledge, this is the largest multicenter
study to report the incidence of IE after TAVR.
This complication is most commonly caused by
staphylococcal, enterococcal, and streptococcal spe-
cies. Our results suggest that the ﬁrst year is a
vulnerable period for infection of the THV, with a
lower incidence of late-onset and higher incidence
of intermediate-onset TAVR-PIE. Lack of complete
endothelialization of the THV may have also con-
tributed to the early infection post-TAVR.
In conclusion, despite timely and aggressive man-
agement, TAVR-PIE is associated with a very high
mortality. Antimicrobial prophylaxis prior to any
invasive procedure is recommended in all TAVR
patients, even late after the procedure. In a post-
TAVR patient with pyrexia and no obvious infec-
tious source, clinicians should have a high index of
suspicion of TAVR-PIE and perform a cautious search
for potential causes of endocarditis. If diagnosed,
these patients should be treated aggressively.*Azeem Latib, MD
Charbel Naim, MD
Michele De Bonis, MD
Jan Malte Sinning, MD
Francesco Maisano, MD
Marco Barbanti, MD
Alessandro Parolari, MD
Roberto Lorusso, MD
Luca Testa, MD
Guglielmo Mario Actis Dato, MD
Antonio Miceli, MD
Sandro Sponga, MD
Francesco Rosato, MD
Carlo De Vincentiis, MD
Nikos Werner, MD
Claudia Fiorina, MD
Antonio Bartorelli, MD
Omar Di Gregorio, MD
Francesco Casilli, MD
Manuela Muratori, MD
Francesco Alamanni, MD
Mattia Glauber, MD
Ugolino Livi, MD
Georg Nickenig, MD
Corrado Tamburino, MD
Ottavio Alﬁeri, MD
Antonio Colombo, MD
*EMO-GVM Centro Cuore Columbus
48 Via M. Buonarroti
20145 Milan
Italy
E-mail: info@emocolumbus.it
http://dx.doi.org/10.1016/j.jacc.2014.09.021
Letters J A C C V O L . 6 4 , N O . 2 0 , 2 0 1 4
N O V E M B E R 1 8 / 2 5 , 2 0 1 4 : 2 1 7 6 – 8 2
2178Please note: Dr. Latib is a consultant for Medtronic and Direct Flow Medical. Dr.
Colombo is a minor shareholder in Direct Flow Medical. Dr. Glauber is a
consultant for Sorin. Dr. Alﬁeri has received royalties from Edwards; and is a
consultant for Symetis. Dr. Maisano is a consultant for Edwards, Medtronic, and
St. Jude Medical. All other authors have reported that they have no relation-
ships relevant to the contents of this paper to disclose. Drs. Latib and Naim
contributed equally to this work.
RE F E RENCE S
1. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;363:139–49.
2. Chu VH, Miro JM, Hoen B, et al. Coagulase-negative staphylococcal pros-
thetic valve endocarditis—a contemporary update based on the International
Collaboration on Endocarditis: prospective cohort study. Heart 2009;95:570–6.
3. Lopez J, Revilla A, Vilacosta I, et al. Deﬁnition, clinical proﬁle, microbio-
logical spectrum, and prognostic factors of early-onset prosthetic valve
endocarditis. Eur Heart J 2007;28:760–5.
4. Habib G, Thuny F, Avierinos JF. Prosthetic valve endocarditis: current
approach and therapeutic options. Prog Cardiovasc Dis 2008;50:274–81.
5. Puls M, Eiffert H, Hunlich M, et al. Prosthetic valve endocarditis after
transcatheter aortic valve implantation: the incidence in a single-centre cohort
and reﬂections on clinical, echocardiographic and prognostic features. Euro-
Intervention 2013;8:1407–18.
APPENDIX For a comprehensive list of the centers and physicians
associated with this study, please see the online version of this article.Coronary Myocardial
Bridges
Pathophysiology and Clinical RelevanceThe recent review by Corban et al. (1) highlights the
limitations of the literature on myocardial bridges
(MBs) and suggests the need for clearly deﬁned terms
and protocols. For example, to clearly establish the
prevalence of MB, clinical identiﬁcation should
require 2 angiographic views obtained after nitro-
glycerin administration, rather than computed
tomography (whose use should probably be limited to
measuring length and depth). Chest pain, myocardial
infarction, and sudden death are not systematically
associated with MB of any anatomic severity; most
MBs are benign. As Corban et al. (1) note, MBs actually
prevent coronary artery disease (CAD) inside affected
segments. Statements regarding pathophysiology,
clinical indications, and adverse effects in MB require
clearly deﬁned inclusion and exclusion criteria
(symptomatic or asymptomatic MB vs. MB with
associated comorbidities that may inﬂuence clinical
presentation, e.g., hypertrophic cardiomyopathy).
To determine the cause of sporadic ischemic symp-
toms, workup must ﬁrst rule out signiﬁcant CAD;
worsening of systolic, phasic arterial narrowing at
MB sites (by dobutamine testing and angiography);
and, especially, spasticity or endothelial dysfunction
(by acetylcholine testing) (2–4).Subselective intraluminal devices (e.g., pressure or
Doppler wires, intravascular ultrasound catheters)
should be generally avoided outside of experimental
protocols because they can alter MB by inducing
spasm and deforming the affected coronary segment
(2,3). Incidentally, the “half-moon” sign associated
with MB probably results from the ﬁberoptic probe
bending at the MB site; it is not a true marker of MB
severity (only of its presence).
Although fractional ﬂow reserve has been advo-
cated (1,2) as a measure of MB clinical severity and the
prognosis of associated CAD, this measurement does
not reveal the hemodynamic severity of MB, nor does
it reﬂect prognosis, as it can in moderate atheroscle-
rotic lesions. Deﬁnitive study of MB will require large,
controlled, prospective, multicenter investigations
with long-term, objective clinical follow-up. Anything
less will only perpetuate the current state of confusion
and uncertainty about this entity.*Paolo Angelini, MD
*Department of Cardiology
Texas Heart Institute
6624 Fannin, Suite 2780
Houston, Texas 77030
E-mail: PAngelini@leachmancardiology.com
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review of the literature. Intern Med 2011;50:2601–6.Myocardial BridgingWe were pleased to see a state-of-the-art review on
myocardial bridging (1), but were surprised by the
authors’ failure to highlight several contemporary
advances in the ﬁeld.
First, it has become clear that traditional adeno-
sine fractional ﬂow reserve (FFR) is inadequate in
testing the hemodynamic signiﬁcance of a myocar-
dial bridge (2). Because myocardial bridging creates
a dynamic stenosis brought on by chronotropic
and inotropic stimulation, simply dilating the artery
